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AbstrACt
background The aggressive clinical behavior of poorly 
differentiated and anaplastic thyroid cancers (PDTC and 
ATC) has proven challenging to treat, and survival beyond 
a few months from diagnosis is rare. Although 30%–60% 
of these tumors contain mutations in the BRAF gene, 
inhibitors designed specifically to target oncogenic BRAF 
have shown limited and only short- lasting therapeutic 
benefits as single agents, thus highlighting the need 
for improved treatment strategies, including novel 
combinations.
Methods Using a BRAFV600E- driven mouse model of ATC, 
we investigated the therapeutic efficacy of the combination 
of BRAF inhibition and oncolytic herpes simplex virus 
(oHSV). Analyses of samples from tumor- bearing mice 
were performed to immunologically characterize the 
effects of different treatments. These immune data were 
used to inform the incorporation of immune checkpoint 
inhibitors into triple combination therapies.
results We characterized the immune landscape in vivo 
following BRAF inhibitor treatment and detected only 
modest immune changes. We, therefore, hypothesized 
that the addition of oncolytic virotherapy to BRAF inhibition 
in thyroid cancer would create a more favorable tumor 
immune microenvironment, boost the inflammatory status 
of tumors and improve BRAF inhibitor therapy. First, we 
showed that thyroid cancer cells were susceptible to 
infection with oHSV and that this process was associated 
with activation of the immune tumor microenvironment 
in vivo. Next, we showed improved therapeutic responses 
when combining oHSV and BRAF inhibition in vivo, although 
no synergistic effects were seen in vitro, further confirming 
that the dominant effect of oHSV in this context was likely 
immune- mediated. Importantly, both gene and protein 
expression data revealed an increase in activation of T cells 
and natural killer (NK) cells in the tumor in combination- 
treated samples. The benefit of combination oHSV and 
BRAF inhibitor therapy was abrogated when T cells or 
NK cells were depleted in vivo. In addition, we showed 
upregulation of PD- L1 and CTLA-4 following combined 
treatment and demonstrated that blockade of the PD-1/PD- 
L1 axis or CTLA-4 further improved combination therapy.
Conclusions The combination of oHSV and BRAF 
inhibition significantly improved survival in a mouse model 
of ATC by enhancing immune- mediated antitumor effects, 
and triple combination therapies, including either PD-1 or 
CTLA-4 blockade, further improved therapy.
bACkground
Poorly differentiated and anaplastic thyroid 
cancers (PDTC and ATC) are rare, but highly 
aggressive, forms of thyroid cancer which 
have few effective treatment options. The 
BRAFV600E mutation is the most common 
somatic mutation (approximately 60%) 
driving this disease, and several studies have 
suggested a link between BRAF mutation 
status and tumor aggression.1–4 Although 
BRAF inhibitors (BRAFi) may yield short- term 
clinical benefits,5–7 monotherapy- targeted 
BRAF inhibition has been disappointing 
overall in clinical trials for PDTC/ATC.8 
Improved efficacy has been observed with 
combined inhibition of BRAF and MEK 
kinases, a combination that also enhanced 
antitumor activity in mouse models.9 Based 
on the encouraging results from a phase II 
trial (NCT02034110), combined dabrafenib/
trametinib has been approved by the Food 
and Drug Administration (FDA) for BRAF- 
mutant ATC since 2018.10 However, experi-
ence from thyroid and other tumors types 
suggests that patients receiving single agent 
or combined kinase inhibitor therapy will 
almost invariably develop resistance to treat-
ment. Therefore, it is important to explore 
other combination strategies incorporating 
a BRAFi backbone with the goal of achieving 
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In BRAF- mutant melanoma, the role of BRAF/MEK 
inhibitor combination therapy continues to evolve in 
the context of successful immunotherapy, particularly 
targeting the CTLA-4 and the PD-1/PD- L1 axis.11–15 Such 
sequential or concurrent combinations now need to take 
into account our increasing understanding that targeted 
small molecules can themselves be immunomodulatory 
and alter an immunosuppressive tumor milieu into one 
with more immune- active characteristics, thus supporting 
effective treatment with immune checkpoint blockade.12 
However, using murine models, we and others have 
detected only modest immune- mediated activity of 
BRAFi monotherapy in thyroid cancer.16 17 Nevertheless, 
combining immunotherapy with targeted small mole-
cules is a logical approach in aggressive thyroid cancer 
and has been the subject of limited exploration to date in 
both the preclinical and early clinical setting.
Several studies using immunocompetent murine 
models of thyroid cancer have shown effective results 
using either BRAF inhibition or the multikinase (VEGFR, 
FGFR, PDGFR, RET) inhibitor lenvatinib together 
with immune checkpoint PD-1/PD- L1 blockade.16–18 
However, in these preclinical models, despite significantly 
prolonged survival and reduced tumor growth, mice were 
not cured of their disease, suggesting that there remains 
the opportunity to test additional drugs in combination 
strategies. Immunohistochemical analysis of patient 
tumor samples shows that 23%–81.3% of ATC and 25% 
of PDTC express PD- L1, although the data supporting 
a link between PD- L1 expression and disease aggression 
are conflicting.19 To date, there is no information from 
large clinical trials in aggressive thyroid cancer treated 
with immunotherapies blocking the PD-1/PD- L1 axis, 
although a phase II trial (NCT02688608,  clinicaltrials. gov) 
using pembrolizumab in patients with ATC is ongoing. A 
case study of a patient with ATC treated with vemurafenib 
together with nivolumab showed a remarkable response 
with compete radiographic and clinical remission,20 and 
a further phase Ib/II clinical study (NCT02501086,  clin-
icaltrials. gov) combining lenvatinib and pembrolizumab 
in solid cancers, including thyroid cancers, is recruiting. 
Furthermore, a recent study investigated if resistance to 
kinase inhibitors could be overcome by pembrolizumab, 
but this showed limited benefit in patients with ATC, and 
the authors concluded that better treatment strategies 
incorporating immunotherapy should be explored.21
Given the paucity of effective treatment options for this 
patient group, even with small molecule/standard immu-
notherapy combinations, we designed a study to investi-
gate if immunovirotherapy with oncolytic herpes simplex 
virus (oHSV) would improve therapeutic responses in 
BRAF- mutant thyroid cancer treated with BRAFi. oHSV, 
encoding GM- CSF, has proven successful in melanoma 
trials and T- VEC (talimogene laherparepvec) has been an 
FDA- approved agent for melanoma since 2015.22 Different 
genetically modified versions of HSV have been shown to 
be effective in vitro and in xenograft models of thyroid 
cancer.23–27 We hypothesized that the addition of oHSV to 
BRAF inhibition in thyroid cancer would create a favor-
able tumor immune microenvironment and boost the 
inflammatory status of tumors, enhancing the cytotoxic 
and/or immunogenic effects of BRAFi alone. We used 
immunocompetent murine models of ATC driven by the 
BRAFV600E oncogene and confirmed limited efficacy with 
BRAF inhibition as monotherapy. The addition of oHSV 
to BRAFi significantly improved therapy via natural killer 
(NK) and T cell- mediated immune mechanisms, and 
the combination treatment was associated with increase 
gene expression of CTLA-4 and PD- L1. Subsequently, 
triple therapy using anti- CTLA-4 or anti- PD-1 checkpoint 
blockade further improved outcome, resulting in long- 
term regression of tumors in almost all mice.
Methods
Animal models and cell lines
Using Cre recombinase/loxP technology, we expressed 
BRAFV600E together with Trp53R172H or PTEN deletion 
in the thyrocytes of C57Bl/6 mice.28–30 Cre recombinase 
was under the TPO promoter and recombination started 
from E14.5.31 Mice were genotyped using genomic DNA 
prepared from ear biopsies and PCRs were performed 
using primers for BRAF (5′  GCCCAGGCTCTTTAT-
GAGAA 3′, 5′  AGTC AATC ATCC ACAG AGACCT 3′ and 
5′  GCTTGGCTGGACGTAAACTC 3′), Cre recombinase 
(5′  TGCC ACGA CCAA GTCA CAGCAATG 3′ and 5′  AGAG 
ACGG AAAT CCAT CGCTCG 3′), Trp53 (5′  CTTG GAGA 
CATA GCCA CACTG 3′, 5′  AGCT AGCC ACCA TGGC 
TTGA GTAA GTCTGCA 3′ and 5′  TTAC ACAT CCAG 
CCTC TGTGG 3′) and PTEN (5′  CTCC TCTA CTCC ATTC 
TTCCC 3′ and 5′  ACTCCCACCAATGAACAAAC 3′). The 
murine primary cell lines TBP- B79, TBP-67, TBPt- 2B4D 
and TBPt- 4C4 were established from thyroid tumors 
from TPO- Cre;BrafV600E;Trp53R172H mice (TBP) and TPO- 
Cre;LSL- BrafV600E;PTEN+/fl (TBPt) mice, respectively. 
Tumors were dissociated by mincing and enzymatic diges-
tion in Hank’s balanced salt solution with 0.5 mg/mL 
Collagenase type I- S (Sigma- Aldrich), 0.4 mg/mL Dispase 
II protease (Sigma- Aldrich) and 4% trypsin (0.25% in 
Tris saline) for 1 hour at 37°C with gentle shaking and 
repeated, gentle pipetting. After filtering through a 70 µM 
cell strainer, dissociated cells were plated on standard cell 
culture plates in Dulbecco’s modified Eagle’s medium 
DMEM with 10% heat- inactivated fetal bovine serum 
(FBS) (Gibco), 60 µg/mL penicillin, 100 µg/mL strep-
tomycin and 0.1 mg/mL Primocin (InvivoGen). Four or 
five subcultures were done every 0.5–1.5 hours, transfer-
ring the medium with cells still not attached in order to 
perform a partial purification. Most purified subcultures 
were chosen by genotyping the mutated Braf- floxed allele 
derived from the Cre- Lox recombination technology28 
by PCR and western blotting showing expression of 
BRAFV600E protein. All cell lines were regularly tested 
for mycoplasma using eMyco Plus Mycoplasma PCR 
Detection Kit (iNtRON Biotechnology). Human (8505 c, 
C643) and murine (TBP- B79, TBP-67, TBPt- 2B4D and 
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TBPt- 4C4) thyroid cancer cell lines were used in this 
study. The murine melanoma cell line 4434 (a gift from 
Richard Marais, CRUK Manchester Institute) was used 
as positive control for the BRAF PCR. Human cells were 
cultured RPMI 1640 medium and murine cells in DMEM, 
supplemented with 10% heat- inactivated FBS and 60 µg/
mL penicillin, 100 µg/mL streptomycin and 0.1 mg/mL 
primocin (InvivoGen). Human cell lines were authenti-
cated by short tandem repeat analysis using GenePrint 10 
System (Promega) following the manufacturer’s instruc-
tions and using in- house sequencing facilities. TC1 cells, 
a modified mouse lung epithelial cell line transformed 
with HPV-16 E6 and E7 and oncogenic HRAS, were a 
kind gift from Professor Tzyy- Choou Wu (Johns Hopkins 
University, Baltimore, Maryland, USA) and Professor Eric 
Deutsch (Institute Gustave Roussy, Villejuif, France).
Viruses, compounds
The BRAF inhibitor PLX4720 was purchased from 
3wayPharm and dissolved in dimethyl sulfoxide (DMSO). 
RP1 is a herpes simplex virus type 1 that was provided 
from Replimune. The titer of RP1 was determined by 
plaque- forming assays using Vero cells. Two versions of 
RP1 viruses were used in these studies: RP1-19 (oHSV) 
encoding murine granulocyte/macrophage- colony 
stimulating factor (GM- CSF) and RP1-24 (oHSV- GFP) 
encoding green fluorescent protein (GFP).
histology and immunohistochemistry
Mouse tumors were formalin- fixed, processed and subse-
quently stained with H&E.
Proliferation assays, virus infection assays, crystal violet 
survival assays and western blotting
For proliferation assays, 2000 cells were plated into 96- well 
plates and, after overnight incubation, treated with serial 
dilutions of oHSV or vehicle control (phosphate- buffered 
saline (PBS)) in triplicate as indicated. After 72 hours 
of incubation, viability was measured using the CellTi-
ter- Glo Luminescent Cell Viability Assay Kit (Promega) 
following the manufacturer’s instructions. Relative 
survival was normalized to controls and fitted a sigmoidal 
dose–response (variable slop) curve using GraphPad 
Prism. For virus infection assays, repeated at least twice, 
600,000 cells were plated into 6- well plates and treated 
with oHSV- GFP or vehicle control (PBS) as indicated. 
After 24 or 48 hours, images were taken using Evos FL 
Cell Imaging System (Thermo Fisher Scientific) and cells 
were collected, stained with viability dye eFluor 780 (eBio-
science) for 30 min and fixed with 2% PFA overnight at 
4°C. GFP quantification was analyzed by flow cytometry as 
described below. For crystal violet survival assays, 100,000 
cells were seeded into 24- well plates or 600,000 cells into 
6- well plates and treated with BRAF inhibitor (PLX4720) 
or vehicle control (DMSO) and oHSV or vehicle control 
(PBS) as indicated. Cell survival was determined using 
crystal violet staining as previously described.32 The 
crystal violet cell viability assay is commonly used on 
adherent cells for visualization of live cells by staining 
DNA and protein in a deep purple color. The different 
shades of violet correlate to numbers of alive cells. Dead 
cells are washed off and create non- stained acellular dead 
zones. For western blotting, lysates were obtained directly 
on the culture surface with Cold Spring Harbor buffer 
(1% NP40) containing protease (Complete, Roche) and 
phosphatase inhibitors (phosphoSTOP, Roche) and 
subjected to protein quantification (BCA; Thermo Scien-
tific) prior to western blotting. The following antibodies 
were used: BRAF V600E (RM8) (RevMab Bioscience), 
phosphorylated ERK1/2 (Thr183 and Tyr185) (Sigma 
M8159), ERK2 (Santa Cruz C-14), α-tubulin (Sigma 
T5168).
ex vivo restimulation of splenocytes
Spleens were excised from euthanized mice, kept on ice- 
cold PBS and dissociated in vitro to single cell suspensions 
through a 0.7 µm cell strainer with cold media IMDM 
(Gibco) with 2 mM L- Glutamine, 5% FBS, 24 µg/mL peni-
cillin and 40 µg/mL streptomycin. Red blood cells were 
lysed incubating for 2 min with cold ACK buffer (Thermo 
Fisher) at room temperature. A final cell suspension was 
cultured in IMDM medium (Gibco) with 50 U/mL recom-
binant human interleukin 2 (IL-2), 2 mM L- Glutamine, 
5% FBS, 24 µg/mL penicillin and 40 µg/mL strepto-
mycin. In parallel, the same thyroid tumor cells TBP- B79 
used in the model of the experiment (as described in in 
vivo experiments) and a non- related cancer cell line TC1 
were treated with 1 µM of BRAF inhibitor (PLX4720) or 
vehicle control (DMSO) and multiplicity of infection 
(MOI) =1 of virus or vehicle control (PBS) for 48 hours, 
stimulated with 100 ng/mL of recombinant murine inter-
feron gamma (IFNγ) (First Link UK) for 24 hours and 
washed prior the ex vivo stimulation of the splenocytes. 
After 1 hour of incubation, 1 µL/mL of protein transport 
inhibitor (BD GolgiPlug, Biosciences) was added to the 
ex vivo stimulation, and after 6 hours more of incubation, 
cells were collected, stained and analyzed by flow cytom-
etry as described in the next section. Two- way analysis of 
variance (ANOVA), Tukey’s multiple comparison test was 
performed using Prism Software (GraphPad).
Cell isolation from tissues and flow cytometry analysis
Tumors and tumor- draining lymph nodes (tdLNs) were 
dissected from experimental mice. Tumors were mechan-
ically dissociated with scissors and enzymatic digested with 
RPMI 0.5 mg/mL Collagenase type I- S (Sigma- Aldrich), 
0.4 mg/mL Dispase II protease (Sigma- Aldrich), 0.2 mg/
mL DNase I (Roche) and 4% trypsin (0.25% in Tris 
saline) for 30 min at 37°C with gentle shaking. Resulting 
cell suspension was passed through a 70 µm cell strainer 
with RPMI 5% FBS and 5 mM EDTA. tdLNs were directly 
mushed through a 70 µm cell strainer with RPMI 5% FBS. 
Resulting samples were divided in equals parts for each 
antibody panel set into 96- well round bottom plates and 
incubated with a mouse Fc blocker (BD Pharmingen) 
2.5 µg/mL for tumor samples and 1 µg/mL for lymph 
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node samples at 4°C for 10 min. After, cells were extra-
cellularly stained with relevant antibodies (online supple-
mentary table) in FACS Buffer (PBS 5% FBS) for 1 hour 
at 4°C, permeabilized when necessary with Foxp3/Tran-
scription Factor Staining Buffer Set (eBioscience) for 
30 min at 4°C and intracellularly stained with relevant 
antibodies (online supplementary table 1) in permeabi-
lization buffer 10% FACS Buffer for 30 min at 4°C. All 
samples were fixed with IC fixation buffer (eBioscience) 
for 20 min at room temperature and analyzed the following 
day using LRSII flow cytometer (BD Bioscience), using 
123count eBeads Counting Beads (Invitrogen) for the 
quantification. Resulting data were analyzed using FlowJo 
software, and statistical analysis was performed using non- 
parametric Kruskal- Wallis test/Dunn’s multiple compari-
sons using Prism Software (GraphPad).
gene expression
Tumor- bearing animals were treated as indicated and on 
treatment day 11, mice were sacrificed and tumors were 
dissected and placed in RNAlater RNA stabilization reagent 
(Qiagen). After disruption and homogenization of the 
whole tumors in lysis buffer Buffer RLT (Qiagen) using 
Precellys 24 homogenizer (Bertin Technologies), RNA 
was isolated using RNeasy Mini Kit (Qiagen) following 
the manufacturer’s instructions. RNA concentration was 
determined by NanoDrop, and 80–120 ng of each sample 
was used for the analysis using the nCounter PanCancer 
Immune Profiling Panel (NanoString Technologies). 
Raw NanoString data were preprocessed using R package 
NanoStringNorm (V.1.2.1).33 Genes were assessed for 
differential abundance using voom (TMM normaliza-
tion) with R package limma (V.3.34.9).34 Genes with log2 
fold change >1 and adjusted p value<0.1 were considered 
significant. NanoString analyses were performed in R 
statistical programming language (V.3.4.4). Visualizations 
were generated using in- house plotting libraries imple-
mented in R.
In vivo experiments
For orthotopic injections, TBP- B79 cells (5×105 cells) 
were injected unilaterally into the left thyroid gland of 
C57Bl/6 mice that were 6–8 weeks old (Charles River) 
using surgical methods and a Hamilton syringe. After 
inoculation of cells for 8–10 days, mice were randomized 
and treatment started. Mice received 40 mg/kg of BRAF 
inhibitor (PLX4720) or vehicle control (5% DMSO in 
water) by oral gavage daily. For virus injections, tumors 
were exposed using surgical methods and the virus was 
injected in a single injection into the tumor using a 
Hamilton syringe. A survival experiment was performed 
by utilizing humane endpoints (daily monitoring, >20% wt 
loss, palpable tumors, respiratory distress, poor general 
condition). For subcutaneous injections, TBP- B79 or 
TBP-67 cells (3×106 cells) were injected in the right flank 
of C57Bl/6 females that were 6–8 weeks old. Treatments 
commenced when tumors reached a tumor volume of 
75–100 mm3. BRAF inhibitor (40 mg/kg) was given daily 
throughout the experiment by oral gavage. 5×105 pfu of 
virus was injected in 30–50 µL intratumorally for a total of 
three injections as shown in schematic pictures of each 
figure. 150 µg of anti- CTLA-4 (clone 9H10) and 200 µg 
anti- PD-1 (clone RMP1-14) were given using intraper-
itoneal injections two to three times per week. Tumors 
were measured twice weekly and tumor volumes were 
calculated using the formula: length × width × height 
(mm)× 0.5236. One- way analysis of variance (ANOVA) 
on area under curve (AUC) was performed using Prism 
Software (GraphPad) to compare tumor growth curves. 
For survival experiments, tumors were allowed to reach 
15 mm in any dimension and then sacrificed. The Kaplan- 
Meier survival curves were compared using the log- rank 
(Mantel- Cox) test using Prism Software (GraphPad).
Immune cell depletion experiments
Tumor- bearing animals were treated with BRAFi, oHSV 
and depletion antibodies. One hundred and fifty micro-
grams of in vivo depletion antibodies was injected via 
intraperitoneal injection every second day, starting 1 day 
prior to BRAF inhibition treatment, with a 2- day break 
between the second and third dose. A total of 11 injec-
tions were given. The following antibodies were used: 
anti- CD8 (clone 2.43), anti- CD4 (clone GK1.5), anti- 
NK1.1 (clone PK136) and isotype control (clone LTF-2) 
(InVivoMab, BioXCell). The depletion experiment was 
performed one time (n=6 mice per group).
results
establishment and characterization of brAF-mutant murine 
thyroid cancer models and the immunological effects of single 
modality brAF inhibition or oncolytic virus treatment
In order to mimic BRAF- mutant human advanced thyroid 
cancer in immunocompetent mouse models, we used 
Cre recombinase technology to express BRAFV600E and 
Trp53R172H or loss of PTEN selectively in the thyrocytes 
of C57Bl/6 mice. Consistent with previously published 
studies, we showed that these transgenic animals devel-
oped thyroid tumors within 6–8 weeks (figure 1A). 
Thyroid cancer cell lines derived from these tumors were 
validated as BRAF mutant using PCR and western blot-
ting (figure 1B,C). Furthermore, using western blotting 
and proliferation assays, we showed that these cell lines 
responded to BRAF inhibitors in vitro (figure 1D,E). 
Importantly, these thyroid cancer cell lines engrafted in 
immunocompetent C57Bl/6 mice both orthotopically 
(figure 1F) and subcutaneously, and formed tumors that 
histologically resembled ATC. The tumors presented with 
morphology essentially identical to ATC in human patients 
composed of sheets of markedly atypical cells with large, 
pleomorphic, ovoid to spindled vesicular nuclei with 
clumped, uneven chromatin, and large nucleoli, and with 
numerous apoptotic bodies (figure 1G). On daily treat-
ment with a BRAFi, mice bearing orthotopic TBP- B79 
tumors survived significantly longer than vehicle- treated 
controls; however, all mice had to be culled within 30 
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Figure 1 Establishment and characterization of murine thyroid cancer models. (A) Using transgenic mice on a C57Bl/6 
strain background, we developed a thyroid cancer mouse model driven by oncogenic BRAF (BRAFV600E). These mice were 
further bred with mice carrying Trp53 mutation or PTEN deletion to develop aggressive anaplastic thyroid cancer (ATC). Site- 
specific expression of transgenes was obtained by Cre recombinase/loxP technology and a thyroid- specific promoter, thyroid 
peroxidase, TPO:Cre and recombination started at E14.5. Mice carrying activated transgenes developed tumors exclusively 
in the thyroid lobes. These tumors were dissected and grown into thyroid cancer cell lines in vitro and used for further in 
vitro analysis or for in vivo orthotopic or subcutaneous injections into immunocompetent C57Bl/6 mice. Generated cell lines 
were subsequently named based on which mutations were induced in the corresponding mice: TPO:BRAF:Trp53=TBP and 
TPO:BRAF:Pten=TBPt. Photograph showing representative whole thyroid tumor of TPO:BRAF:Trp53 mouse. Tu, tumor; Tr, 
trachea. (B) Locus recombination of the BRAFV600E transgene in established murine thyroid cancer cell lines was confirmed by 
PCR. The murine melanoma BRAF wild- type cell line 1014 was used as negative control, and the murine melanoma BRAFV600E 
mutant cell line 4434 was used as positive control of the Cre recombinase rearranged LSL- BrafV600E allele. Non- recombined 
DNA from a BRAFV600E mouse served as control for band sizes of wild- type BRAF (WT- Braf) and the LSL- BrafV600E allele.28 
(C) Established murine thyroid cancer cell lines (TBP- B79, TBP-67, TBPt- 2B4D and TBPt- 4C4) were confirmed to express 
oncogenic BRAFV600E by western blot analysis. Lysates from human C643 (BRAF wild- type) and murine 4434 (BRAF V600E 
mutant) cells were used as negative and positive controls, respectively. Tubulin served as loading control. (D) Immunoblots for 
ppERK, total ERK and α-tubulin in murine thyroid cancer cell lines (TBP- B79, TBP-67, TBPt- 2B4D and TBPt- 4C4) following 
treatment with DMSO control or BRAFi (1 µm, 4 hours). (E) Proliferation dose–response curves for murine thyroid cancer cell 
lines (TBP- B79, TBP-67, TBPt- 2B4D and TBPt- 4C4) treated with BRAFi over a period of 72 hours. Cell survival was measured 
with CellTitreGlo and normalized to DMSO- treated controls. (F) Representative photograph of unilateral thyroid tumor (dotted 
box) following injection of the thyroid cancer cell line TBP- B79 into the left thyroid lobe, just adjacent to the trachea of a C57Bl/6 
mouse and left to grow for 4 weeks. Tu, tumor; Tr, trachea; Sg, salivary gland. (G) H&E stained photomicrograph of TBP- B79 
tumor growing in the thyroid of a C57Bl/6 mouse. Scale bar=50 µm. This shows hypercellular tumor, composed of sheets of 
markedly atypical cells with large, pleomorphic, ovoid to spindled vesicular nuclei with clumped, uneven chromatin, and large 
nucleoli. Apoptotic bodies are numerous. The morphology here is essentially identical to ATC in human patients, which typically 
manifests histologically as sheets of markedly atypical spindle cells with the nuclear features described. (H) The thyroid cancer 
cell line TBP- B79 was injected unilaterally into the left thyroid lobe of C57Bl/6 mice. After tumors were established, mice were 
treated by oral gavage with vehicle or BRAF inhibitor (40 mg/kg) daily throughout the experiment. Kaplan- Meier survival graph 
displaying the survival of the animals treated with vehicle control or BRAF inhibitor (survival=palpable measurable neck mass 
of maximum 10 mm combined with clinical signs of disease). Statistical analysis: survival curve comparison using log- rank 
(Mantel- Cox) test. (**p=0.0027) was performed using Prism Software (GraphPad). BRAFi, BRAF inhibitor.
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days due to disease progression (figure 1H). To address 
the immune consequences of BRAFi treatment in this 
model, we performed flow cytometry analysis of orthot-
opic tumors, which revealed limited immune effects from 
treatment (online supplementary figure 1A). Four days of 
daily BRAF inhibition did not increase numbers of T cells 
or the CD8:Treg ratio within tumors (data not shown), 
nor did this treatment result in a significant increase in 
proliferation (as assessed by Ki67) of effector CD4+ T 
cells (Teff), regulatory CD4+ T cells (Treg) or CD8+ T 
cells in tumors (online supplementary figure 1B). Gran-
zyme B (GzmB) positivity was used as a measurement of 
T cell functional activity, but this again did not signifi-
cantly change (online supplementary figure 1C). Taken 
together, these data led us to hypothesize that the posi-
tive effects of BRAF inhibition on tumor growth could be 
further improved by boosting antitumor immunity in the 
context of BRAF inhibitor cytotoxicity, using oncolytic 
virotherapy. Therefore, we next tested whether oHSV 
could stimulate the immune tumor microenvironment 
(TME) within orthotopic thyroid tumors (online supple-
mentary figure 1D). A single intratumoral injection of 
oHSV increased both the proliferation and activation of 
CD8+ T cells, supporting the application of combined 
oHSV/BRAFi therapy as a potentially immunogenic, 
as well as directly cytotoxic, strategy for thyroid cancer 
(online supplementary figure 1E and F).
Combining ohsV and brAFi enhances antitumor activity in 
vivo, but not in vitro
Subsequently, we set out to test if the combination of the 
two different treatments would act synergistically. Using 
both human and murine thyroid cancer cell lines, we 
observed tumor cell infection and cell killing by oHSV in 
vitro in a dose- dependent manner (figure 2A–C). However, 
using two murine cell lines, the addition of BRAFi to 
oHSV in vitro did not further increase the effect of the 
virus alone (figure 2D,E). Despite the lack of synergistic 
effects in vitro, we decided to test the combination in vivo 
in immunocompetent mouse models, since our hypoth-
esis was that oHSV might improve therapy by enhancing 
the immunogenicity of tumor cell death, rather than 
the direct cytotoxicity of BRAF inhibition. Since oHSV is 
administered intratumorally and we were limited to one 
oHSV injection into the orthotopic model (due to animal 
welfare constraints in the context of a tumor seeded in the 
neck), we used a subcutaneous tumor model for these, 
and subsequent, experiments. Furthermore, subcutane-
ously implanted tumors also allow easier monitoring and 
measurement of tumor growth in therapy experiments. 
Importantly, we compared the immune cell infiltrate 
in response to short- term (2 days) oHSV treatment in 
tumors seeded orthotopically or in the flank, and found 
no significant differences between them. Using the TBP- 
B79 model in immunocompetent mice, tumor- bearing 
animals were treated as outlined in figure 3A. Combina-
tion treatment with oHSV and BRAF inhibition delayed 
tumor growth and increased median survival, which was 
22.5 days (vehicle), 25 days (oHSV), 28 days (BRAFi) and 
37.5 days (oHSV/BRAFi) (figure 3B,C). Consistent with 
the lack of synergistic effects of combination treatment in 
vitro, on measurement by ex vivo plaque assays, we did not 
retrieve increased amounts of virus from oHSV/BRAFi- 
treated tumors relative to the dose injected, or compared 
with those treated with oHSV only (data not shown). This 
indicates that the enhanced therapy seen with the combi-
nation in vivo was unlikely due to increased viral replica-
tion, and more likely to be immune- mediated. To explore 
further the mechanisms underlying combination therapy, 
we assessed whether single modality or combination treat-
ment resulted in adaptive T cell priming, by restimulating 
splenocytes from treated mice ex vivo with TBP- B79 cells, 
or an irrelevant tumor cell line control. Restimulation of 
splenocytes from oHSV/BRAFi- treated mice with TBP- 
B79 induced significant intracellular IFNγ in responder 
CD8+ splenic T cells, consistent with priming of a specific 
antitumor cytotoxic T cell response following combina-
tion therapy (figure 3D).
gene expression profiling highlights an important role for 
activated t cells in ohsV/brAFi treatment, and suggests the 
Pd-1/Pd-l1 axis and CtlA-4 as targets for triple combination 
therapies
Although we saw effective combination therapy with 
oHSV/BRAFi in terms of thyroid tumor growth inhibi-
tion in vivo, we did not achieve full tumor control and 
resistance to treatment emerged relatively rapidly. There-
fore, gene expression profiles of treated tumors were 
analyzed using NanoString nCounter technology to 
more fully characterize the immune microenvironment, 
covering tumor, stromal and immune components, in an 
attempt to identify further targets for additional combina-
tion strategies. Mechanistically, gene expression data and 
subsequent cell type clustering of differentially expressed 
genes suggested that the improved therapy conferred by 
oHSV/BRAFi combination was mediated through activa-
tion of T cells (online supplementary figure 2A and B). 
Importantly, the gene expression analysis also identified 
potential targets for further immunotherapy interven-
tions. Specifically, oHSV/BRAFi treatment significantly 
upregulated both PD- L1 and PD- L2, as well as CTLA-4, 
providing rationale for the addition of PD-1/PD- L1 or 
CTLA-4 blockade to oHSV/BRAFi to further improve 
therapy (online supplementary figure 2B). In contrast, 
no significant changes were seen in the expression of the 
other potentially targetable negative immune checkpoint 
molecules, namely, TIGIT, LAG-3 and TIM-3 (data not 
shown).
both innate and adaptive immunity contribute to the efficacy 
of ohsV/brAFi combination treatment through activation of 
immune effector cells in tumors and in draining lymph nodes
Next, we wanted to explore the ability of combina-
tion oHSV/BRAFi treatment phenotypically to activate 
immune cell subsets. This analysis allowed us to consol-
idate the flow cytometry data shown for single modality 
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Figure 2 In vitro effects of oHSV on human and murine thyroid cancer cell lines. (A) Human (8505 c) and murine (TBP- B79 
and TBP-67) thyroid cancer cell lines were infected with oHSV- GFP at various MOIs and cells were imaged for virus replication 
(visualized by GFP signal) at indicated time points post- infection. Corresponding bright- field images show cell morphology 
changes following virus infection. (B) Human (8505 c and C643) and murine (TBP- B79, TBP-67, TBPt- 2B4D and TBPt- 4C4) 
thyroid cancer cell lines were infected with 1:3 dilutions of oHSV starting at MOI 100 or left uninfected as controls and cell 
survival was measured 72 hours later using CellTitreGlo assay. (C) Human (8505 c) and murine (TBP- B79, TBP-67, TBPt- 2B4D 
and TBPt- 4C4) thyroid cancer cell lines were infected with oHSV (MOI 0.1 or 1) or left uninfected and cells were fixed and 
stained with crystal violet 48 hours later. (D) Murine thyroid cancer cell lines (TBP- B79 and TBP-67) were infected with oHSV- 
GFP (MOI 0.1 or 1) or left uninfected, and subsequently treated with BRAF inhibitor (BRAFi) (0.1 or 1 µM). Cells were analyzed 
for GFP positivity (virus infection) using flow cytometry 48 hours post- treatment. (E) Murine thyroid cancer cell lines (TBP- B79 
and TBP-67) were infected with oHSV at various MOI and treated with BRAFi at indicated concentrations. Cells were fixed and 
stained with crystal violet 48 hours later. Each experiment was performed a minimum of two times with similar results. BRAFi, 
BRAF inhibitor; GFP, green fluorescent protein; oHSV, oncolytic herpes simplex virus.
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Figure 3 Combination treatment with oHSV/BRAFi delays tumor growth and increases survival in an immunocompetent 
mouse model of thyroid cancer. (A) C57Bl/6 mice (n=6/group) were subcutaneously implanted with murine thyroid cancer 
cell line TBP- B79 in the right flank (3×106 cells/mouse) and mice were treated with single agent BRAFi (40 mg/kg daily 
by oral gavage), oHSV (5×105 pfu × 3 by intratumoral injection) or both agents in combination, starting on day 10 post 
implantation of cells. (B) Tumor growth curves with data presented as mean±SEM. Tumor growth curves were compared 
using ordinary one- way analysis of variance (ANOVA) on AUC (area under curve) between day 0 and day 23 using Prism 
Software (GraphPad)=vehicle vs oHSV: *Vehicle vs BRAFi: ***Vehicle vs oHSV/BRAFi: ****oHSV vs BRAFi: ns, oHSV vs oHSV/
BRAFi: *BRAFi vs oHSV/BRAFi: ns. (C) Kaplan- Meier survival graph displaying the survival of the animals treated with different 
therapies or vehicle control (survival=a tumor measures 15 mm in any dimension). Median survival: 22.5 days (vehicle), 25 days 
(oHSV), 28 days (BRAFi) to 37.5 days (oHSV/BRAFi). Kaplan- Meier survival curves were compared using the log- rank (Mantel- 
Cox) test using Prism Software (GraphPad)=vehicle vs oHSV: ns, vehicle vs BRAFi: *p value 0.0165, vehicle vs oHSV/BRAFi: **p 
value 0.0011, oHSV vs BRAFi: ns, oHSV vs oHSV/BRAFi: * p value 0.0111, BRAFi vs oHSV/BRAFi: ns. (D) Ex vivo IFNγ memory 
recall assay. Intracellular IFNγ production, measured by flow cytometry, in CD8+ splenocytes using flow cytometry was used 
to measure immune cell activation and recall responses towards live TBP- B79 tumor cells. The unrelated murine cell line TC1 
was used as control. Statistical analysis: two- way analysis of variance, Tukey’s multiple comparison test was performed using 
Prism Software (GraphPad). Each experiment was performed twice with similar results. BRAFi, BRAF inhibitor; IFNγ, interferon 
gamma; ns, not significant; oHSV, oncolytic herpes simplex virus.
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Figure 4 Recruitment and activation of natural killer (NK) cells in tumors. C57Bl/6 mice (n=6/group) were subcutaneously 
implanted with the murine thyroid cancer cell line TBP- B79 in the right flank (3×106 c/mouse) and mice were treated with BRAFi 
(40 mg/kg daily by oral gavage) and oHSV (5×105 pfu × 3 injections by intratumoral injection) as single agents or in combination. 
On treatment day 7, tumors were dissected and tumor- infiltrating lymphocytes (TILs) were analyzed via flow cytometry. (A) 
Treatment and collection schedule for TBP- B79 tumor model. (B) Percentage of NK cells/CD45+ cells and percentage of Ki67+, 
CD69+, GzmB+ NK cells in tumors. (C) Percentage of NK cells/CD45+ cells and percentage of CD69+ and GzmB+ NK cells 
in tumor- draining lymph nodes. Each dot represents an individual mouse. Statistical analysis: non- parametric Kruskal- Wallis 
test/Dunn’s multiple comparisons were performed using Prism Software (GraphPad). Comparison with p values over 0.05 are 
deemed not statistically significant. (NK cells: CD45+, CD3-, NK1.1+). The experiment was performed twice with similar results. 
BRAFi, BRAF inhibitor; oHSV, oncolytic herpes simplex virus; LN, lymph nodes.
treatment in the orthotopic model shown in online 
supplementary figure 1, and to test consistency between 
immune cell flow cytometry characterization, and the 
transcriptomic data of online supplementary figure 2. 
Moreover, while direct intratumoral injection of oHSV 
is currently the only approved oncolytic virotherapy, 
it remains unclear to what extent the immune conse-
quences of viral administration by this route are restricted 
to the TME, or whether they are also seen locoregion-
ally, particularly in tdLNs. We, therefore, treated TBP- B79 
tumor- bearing mice with oHSV, BRAFi or the combina-
tion (figure 4A) and characterized the immune cells 
within both tumors and tdLNs using flow cytometry. 
With respect to the innate response, we found an small 
increase in the percentage of NK cells within CD45+ cells 
following combination treatment in tumors but not in 
tdLNs (figure 4B,C). However, NK cells in both tumors 
and tdLNs were activated by treatment, as measured by 
their expression of Ki67, GzmB and CD69 (figure 4B,C).
With regard to T cells, mice were treated as indi-
cated in figure 5A, and the CD8:Treg ratio in the tumor 
increased with treatment, as did proliferation (Ki67+), 
GzmB expression and CXCR3 expression of CD4+ effec-
tors, CD4+ Tregs and CD8+ T cell subsets (figure 5B–E). 
This was consistent with granzymes and CXCR3 as prom-
inent hits of differentially expressed genes in the tumor 
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Figure 5 Combined treatment with oHSV/BRAFi activates T cells and depletion of CD8+ T cells or natural killer (NK) cells 
abrogates the effects on tumor growth. C57Bl/6 mice (n=6/group) were subcutaneously implanted with the murine thyroid 
cancer cell line TBP- B79 in the right flank (3×106 c/mouse) and mice were treated with BRAFi (40 mg/kg daily by oral gavage) 
and oHSV (5×105 pfu × 3 injections by intratumoral injection) as single agent or in combination. On treatment day 11, tumors 
and tumor- draining lymph nodes were dissected and lymphocytes analyzed via flow cytometry. (A) Treatment and collection 
schedule for TBP- B79 tumor model. (B) Ratio of tumor- infiltrating lymphocytes (TILs) (CD8/CD4reg). (C) Percentage of Ki67+ 
CD4 eff, CD4reg or CD8+ cells. (D) Percentage of GzmB+ CD4 eff, CD4reg or CD8+ cells. (E) Percentage of CXCR3+ CD4 eff, 
CD4reg or CD8+ cells. (F) Percentage of PD-1+ TILs: CD4eff, CD4reg and CD8+ T cells. (G) Percentage of CTLA-4+ TILs: 
CD4eff, CD4reg and CD8+ T cells. (H) percentage of Ki67+ CD4 eff, CD4reg or CD8+ cells in tumor- draining lymph nodes. (I) 
Percentage of CXCR3+ lymphocytes in tumor- draining lymph nodes: CD4eff, CD4reg and CD8+ T cells. (J) Percentage of PD-
1+ lymphocytes in tumor- draining lymph nodes: CD4eff, CD4reg and CD8+ T cells. (K) Percentage of CTLA-4+ lymphocytes in 
tumor- draining lymph nodes: CD4eff, CD4reg and CD8+ T cells. Each dot represents an individual mouse. Statistical analysis: 
non- parametric Kruskal- Wallis test/Dunn’s multiple comparisons were performed using Prism Software (GraphPad). Comparison 
with p values over 0.05 is deemed not statistically significant. Teff (CD4+/FoxP3-) and Treg (CD4+/FoxP3+). The experiment 
was performed four times with similar results. (L) C57Bl/6 mice (n=6/group) were subcutaneously implanted with murine thyroid 
cancer cell line TBP- B79 in the right flank (3×106 cells/mouse) and mice were treated with single agent BRAFi (40 mg/kg daily by 
oral gavage), oHSV (5×105 pfu × 3 by intratumoral injection) or both agents in combination. D.Ab: depletion antibodies (isotype, 
aCD8, aNK1.1, aCD4) were administered every second day 150 μg by intraperitoneal injection for a total of 11 injections. (M) 
Tumor growth curves showing tumor volume over time. Tumor growth curves were compared using ordinary one- way analysis 
of variance (ANOVA) on AUC (area under curve) between day 0 and day 41 using Prism Software (GraphPad). oHSV/BRAFi/
isotype vs oHSV/BRAFi/aCD4: ns, oHSV/BRAFi/isotype vs oHSV/BRAFi/aCD8: **adj. p value 0.0093, oHSV/BRAFi/isotype vs 
oHSV/BRAFi/aNK1.1: **adj. p value 0.0057, oHSV/BRAFi/aCD4 vs oHSV/BRAFi/aCD8 ns, oHSV/BRAFi/aCD4 vs oHSV/BRAFi/
aNK1.1 ns, oHSV/BRAFi/aCD8 vs oHSV/BRAFi/aNK1.1 ns. BRAFi, BRAF inhibitor; ns, not significant; oHSV, oncolytic herpes 
simplex virus; LN, lymph node.
transcriptomic data (online supplementary figure 2). 
PD-1 expression was increased by treatment on tumor 
CD8+ T cells, but decreased on Treg cells, and was 
unchanged on CD4+ effectors (figure 5F), while CTLA-4 
increased on CD4+ effectors and CD4+ Tregs, but was 
unchanged on CD8+ cells (figure 5G). In general, the 
changes in the tumors were mirrored by T cells in the 
tdLNs; in particular, PD-1 expression increased on CD4+ 
effectors as well as CD8+ cells, although CTLA-4 increased 
significantly only on CD4+ effector cells (figure 5H–K). 
Furthermore, consistent with the gene expression 
data, we did not detect any changes in TIGIT, LAG-3 
or TIM-3 on lymphocytes in tumors (data not shown). 
Importantly, the CD8:Treg ratio and activation status of 
T cells in tumors and tdLNs were further validated in a 
second tumor model using TBP-67 cells (online supple-
mentary figure 3A–I). Taken together, these effects of 
combination oHSV/BRAFi therapy on T cell activation 
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were consistent with the tumor transcriptomic data and 
support the targeting of PD-1 and CTLA-4 to further 
improve therapy.
To confirm the contribution of the innate and adap-
tive arms of the immune response to the in vivo efficacy 
of oHSV/BRAFi combination therapy, we tested the 
dependence of therapy on specific immune cell subsets. 
TBP- B79 tumor- bearing mice were treated with oHSV/
BRAFi and depleted of NK cells, CD4+ T cells or CD8+ 
T cells (figure 5L). This showed that depletion of either 
NK cells or CD8+ T cells significantly reduced the anti-
tumor efficacy of oHSV/BRAFi treatment compared 
with isotype control- treated mice (figure 5M). In addi-
tion, depletion of CD4+ T cells showed a similar trend, 
although this did not reach statistical significance 
(figure 5M).
blockade of either Pd-1 or CtlA-4 further enhances the 
therapeutic efficacy of ohsV/brAFi therapy
To investigate if the upregulation of the PD-1/PD- L1 axis 
and CTLA-4 in tumors and tdLNs (online supplementary 
figures 2 and 3 and figure 5) could be therapeutically trac-
table, we set up triple combination experiments including 
oHSV, BRAFi and anti- PD-1 or anti- CTLA-4 (figure 6A). 
Since both PD- L1 and PD- L2 were transcriptionally upreg-
ulated following combination therapy, we chose to use an 
anti- PD-1 antibody to target both immune checkpoints in 
our experiments. Both triple combinations significantly 
reduced TBP- B79 tumor growth and prolonged survival 
compared with single or double- agent combinations 
(figure 6B,C and online supplementary figure 4A‒E). 
We were not able to address whether the combination of 
anti- PD1 and anti- CTLA-4 was better than either antibody 
alone within this triple modality combination, because 
blockade of even a single negative immune checkpoint 
resulted in almost complete tumor control in this model. 
We did not see any weight loss or other toxicity in mice 
treated with any single, double or triple combination 
therapies (data not shown). Using the treatment regimen 
outlined in figure 6A, five out of six animals in each of the 
triple combination groups were cured of their tumors. 
Importantly, when these animals were rechallenged with 
tumor cells on the contralateral flank, previously cured 
mice did not develop tumors while all naïve control 
mice did, suggesting that protective immunity had devel-
oped (figure 6D). This is consistent with the CD8+ T cell 
involvement and dependence shown in online supple-
mentary figures 2 and 3 and in figure 5. In addition, mice 
treated with triple combination therapy had an increase 
of intratumoral CD45+ cells per gram of tumor compared 
with other treatment groups (figure 6E). To investigate 
if the therapeutic benefit of CTLA-4 blockade might be 
due to Treg depleting properties of the anti- CTLA-4 anti-
body we analyzed the numbers of Treg cells in the tumors, 
and found a significant decrease in intratumoral Tregs in 
triple combination- treated mice compared with oHSV/
BRAFi- treated mice (figure 6F).
dIsCussIon
PDTC and ATC are very aggressive forms of cancer and 
among the most rapidly proliferating tumors in humans. 
Typically, survival for more than 12 months beyond diag-
nosis is uncommon. In this study, we describe the estab-
lishment of murine ATC cell lines that can be used as tools 
for studies in immunocompetent models to replicate 
human disease. These mouse cancer cell lines are synge-
neic to C57Bl/6 mice, have genetic alterations consistent 
with human tumors, are transplantable to immunocom-
petent host mice in orthotopic or subcutaneous models 
and can be used to study cancer immunology.
Since kinase inhibitors (including BRAFi) are important 
drugs in the management of aggressive thyroid cancer, 
we first showed that BRAF mutant ATC is responsive to 
BRAFi monotherapy, although only transiently. Since 
BRAFi in the treatment of melanoma has been shown to 
be potentially immunostimulatory within the TME,35–38 
we tested whether BRAFi monotherapy was immunogenic 
in our ATC model, but found only limited changes in the 
immune landscape in orthotopic tumors. In contrast, a 
single intratumoral injection of HSV did impact on the 
TME in an orthotopic model, increasing both prolif-
eration and activation of CD8+ T cells within targeted 
tumors.
PDTC and ATC are attractive candidates for treatment 
with oHSV as they are readily targetable for direct injec-
tion. In addition, we found that thyroid cancer cell lines 
are infectible with, and killed by, oHSV in vitro, although 
this sensitivity was not affected by the addition of BRAFi. 
These results contrast somewhat with a study combining 
oHSV and MEK inhibition in melanoma cells, in which 
the investigators detected increased cytotoxicity of oHSV, 
as well as increased in vitro viral replication, if the cells 
were pretreated with MEKi.39 It is noteworthy that their 
studies were performed mainly in human cell lines with 
much greater sensitivity to the virus alone, while all ours 
were performed in murine systems. Also, there might 
be differences in models (melanoma vs thyroid cancer) 
and differences in viral replication in vivo might occur 
at specific time points that depend on the model system. 
Importantly, in our study, the combination of oHSV 
and BRAFi was more effective in vivo, confirming our 
hypothesis that the immune- stimulatory capacity of oHSV 
might enhance the cytotoxic effects of BRAFi alone. The 
immune- mediated effects of oHSV/BRAFi combination 
treatment were confirmed by their dependence on NK 
and T cells and the association with priming of specific, 
adaptive antitumor immunity.
To further explore the consequences of combined 
oHSV/BRAFi treatment for thyroid cancer, we carried 
out gene expression analysis, which includes the contri-
bution of non- immune cells within the TME (including 
tumor cells and fibroblasts) to the tumor transcriptome. 
Consistent with the immune- mediated activity of the 
oHSV/BRAFi combination, we found evidence of NK and 
T cell activation associated with effective therapy. Many 
of the significantly upregulated genes (covering innate 
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Figure 6 Triple combination with oHSV/BRAFi and anti- PD-1 or anti- CTLA-4 further improves therapeutic responses. (A) 
C57Bl/6 mice (n=6/group) were subcutaneously implanted with murine thyroid cancer cell line TBP- B79 in the right flank 
(3×106 c/mouse), and mice were treated with BRAFi (40 mg/kg daily by oral gavage) and oHSV (5×105 pfu × 3 by intratumoral 
injection) and anti- PD-1 (200 µg, intraperitoneal injection) or anti- CTLA-4 (150 µg, intraperitoneal injection) therapeutic antibodies 
or relevant controls as indicated. (B) Tumor growth curves with data presented as mean±SEM. Tumor growth curves were 
compared using ordinary one- way analysis of variance (ANOVA) on AUC (area under curve) between day 0 and day 30 using 
Prism Software (GraphPad). Vehicle vs oHSV/BRAFi: ****adj. p value<0.0001, vehicle vs oHSV/BRAFi/aCTLA-4: ****adj. p 
value<0.0001, vehicle vs oHSV/BRAFi/aPD-1: ****adj. p value<0.0001, oHSV/BRAF vs oHSV/BRAFi/aCTLA-4: ns, oHSV/BRAFi 
vs oHSV/BRAFi/aPD-1: ns, oHSV/BRAFi/aCTLA-4 vs oHSV/BRAFi/aPD-1: ns. (C) Kaplan- Meier survival graph displaying the 
survival of the animals treated with different therapies. Kaplan- Meier survival curves were compared using the log- rank (Mantel- 
Cox) test using Prism Software (GraphPad). (D) Mice cured of their tumors were rechallenged on the left flank with 3×106 cells 
and tumor growth monitored. Treatment groups included different numbers of cured mice: oHSV/BRAFi (n=1), oHSV/BRAFi/
aPD-1 (n=5) and oHSV/BRAFi/aCTLA-4 (n=5). Six naïve mice served as controls. Tumor growth curves were compared using 
ordinary one- way ANOVA on AUC (area under curve) between day 0 and day 20 using Prism Software (GraphPad). Naïve vs 
oHSV/BRAFi/isotype: ***adj. p value 0.0006, naïve vs oHSV/BRAFi/aCTLA-4: ****adj. p value<0.0001 and naïve vs oHSV/BRAFi/
aPD-1: ****adj. p value<0.0001. (E) C57Bl/6 mice (n=6/group) were subcutaneously implanted with the murine thyroid cancer 
cell line TBP- B79 in the right flank (3×106 c/mouse) and mice were treated with BRAFi (40 mg/kg daily by oral gavage) and 
oHSV (5×105 pfu × 3 injections by intratumoral injection) and anti- CTLA-4 (150 µg) by intraperitoneal injection as single agent 
or in combination. On treatment day 11, tumors and tumor- draining lymph nodes were dissected and lymphocytes analyzed 
via flow cytometry. CD45+ cells/ gram tumor is presented. (F) Percentage of FoxP3+CD4 reg/CD45+ cells are presented. Each 
dot represents an individual mouse. Statistical analysis: non- parametric Kruskal- Wallis test/Dunn’s multiple comparisons 
were performed using Prism Software (GraphPad). Comparison with p values over 0.05 is deemed not statistically significant. 
Statistical analysis of flow cytometry data: two- way ANOVA (Tukey’s multiple comparison test), one- way ANOVA or non- 
parametric Kruskal- Wallis test followed by Dunn’s multiple comparison test, or unpaired non- parametric Mann- Whitney test 
were performed depending on sample size and numbers of groups analyzed as indicated in the different experiments using 
Prism Software (GraphPad). Tumor growth curves are presented as mean±SEM and growth curves compared calculating AUC 
followed by one- way ANOVA. Kaplan- Meier survival curves were compared with the log- rank (Mantel- Cox) test using Prism 
Software (GraphPad). BRAFi, BRAF inhibitor; ns, not significant; oHSV, oncolytic herpes simplex virus.
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immunity more widely, including interferons, as well as 
NK and T cell activation), have been previously published 
as reflecting ‘T- cell inflamed’ tumors, and overlap with 
genes upregulated in melanoma patients responding to 
BRAFi/MEKi/anti- PD-1 treatment.11 40 Transcriptomic 
analysis of tumors can also be used to identify immune- 
based treatment targets and our data specifically revealed 
upregulation of CTLA-4, PD- L1 and PD- L2 in tumors, 
providing a rationale for triple combination strategies 
including CTLA-4 and PD-1 blockade.41 42 Importantly, 
inhibitors of CTLA-4 and PD-1/PD- L1 are frequently 
used in the clinic, have known and manageable toxicity 
profiles, and are part of standard clinical care in an 
increasing range of cancers. Addition of either anti- 
CTLA-4 or anti- PD-1 antibodies significantly further 
improved oHSV/BRAFi therapy, resulting in almost 
complete tumor control in our model. Cured mice were 
then protected from secondary re- challenge, further vali-
dating the immune contribution to effective therapy.
The combination MEKi/HSV/aPD-1 led to increased 
survival in a mouse melanoma model39 and it would, 
therefore, be tempting to speculate that similar strategies 
including MEKi would show therapeutic benefit in BRAF 
wild- type thyroid cancers. Alternative ways to achieve 
MAPK pathway blockade in combination with oHSV in 
thyroid cancer could include double inhibition of BRAF 
and MEK using either BRAFi/MEKi combinations, which 
is a standard treatment for BRAF mutant melanoma 
patients, or pan- RAF inhibitors, to overcome or delay 
resistance to MAPK pathway inhibition and potentially 
increase therapeutic benefit in combination with oHSV. 
However, both panRAF and MEK inhibitors are less 
tumor cell- specific than BRAFV600E inhibitors, and would 
potentially negatively affect proliferation of immune cells 
or other non- tumor cells in the TME. Although poten-
tially interesting, these studies incorporating further 
small molecule drugs are beyond the scope of the current 
investigation.
It is interesting that a phase III study in melanoma 
has shown potential clinical benefit and a favorably 
altered TME from combining oHSV (TVEC) with 
anti- PD-1 (pembrolizumab)43 and other clinical trials 
involving combinations of T- VEC with anti- PD-1 therapy 
in sarcoma, lung cancer studies, breast and melanoma 
are ongoing ( clinicaltrials. gov). Of interest is a recent 
paper by Zhu and colleagues who used a modified oHSV2 
virus encoding an antibody against PD-1. oHSV2- aPD-1 
treatment induced durable antitumor response and had 
superior therapeutic efficacy over unmodified oHSV2 or 
aPD-1 blockade alone.44
Analysis focused on innate (NK) and adaptive (CD8+ 
effectors, CD4+ effectors and CD4+ Treg) tumor- 
infiltrating immune cells at the protein level by flow 
cytometry supported the tumor gene expression data. Of 
note is the fact that increased numbers and activity of NK 
cells were detected when we analyzed tumors at an early 
time point. Tumor NK cells were activated by treatment, 
effects which were shown to be due primarily to oHSV 
rather than BRAFi, when monotherapy and combination 
treatment groups were compared. Interestingly, human 
ATC cells are able to attract CXCR3- positive NK cells and 
are sensitive to NK cell- mediated lysis.45 The same pattern 
was seen on activation of T cells within tumors by virus. 
With regard to tumor T cell checkpoint protein expres-
sion, CTLA-4 was increased on CD4+ T effectors and Treg 
though this change was not clearly associated with oHSV 
rather than BRAFi treatment. Given the potential role 
for Treg depletion by anti- CTLA-4 antibodies in immu-
notherapy,46 we specifically investigated the numbers of 
Tregs following triple combination treatment (oHSV/
BRAFi/anti- CTLA-4) and found fewer Tregs in this treat-
ment context. This suggests that anti- CTLA-4- mediated 
Treg depletion may play a role in this triple combination 
treatment regimen, although the various mechanisms by 
which immune checkpoint blockade may act remain to be 
fully elucidated in this and other contexts. For example, 
studies of human samples have not detected depletion 
of FoxP3+ Tregs by anti- CTLA-4 treatment, although 
these differences might depend on factors such as the 
time points available post- treatment for analysis.47 In our 
study, PD-1 expression showed a virus- mediated increase 
on tumor CD8+ T cells and reduction on Tregs, despite 
the lack of significant upregulation in PD-1 expression 
as assessed by NanoString in whole tumors (log2 fold 
change 0.38, p value: 0.357). However, consistent with 
this, we have previously found that PD-1 transcription is 
not necessarily mirrored by protein expression levels.48 
We have not specifically investigated levels of PD-1 on NK 
or other cells, and we cannot exclude that the therapeutic 
benefit seen with PD-1 blockade could be due to its effect 
on cells other than T cells.
Analysis of tdLNs showed very similar changes in NK 
and T cell activation as those seen in tumors on treat-
ment, suggesting that even local intervention by oHSV 
injection can modify the locoregional, as well as the 
tumor, immune microenvironment.49 However, the rela-
tive contribution to therapy of tumor versus locoregional 
immune activation remains unclear. To investigate if 
local administration of oHSV activates immune effector 
cells and molecules both in the TME and in the systemic 
immune system, spleens in addition to tdLNs could be 
analyzed. Interestingly, oHSV2- aPD-1 treatment has been 
shown to induce a similar trend of immune activation 
of splenocytes compared with tumors using NanoString 
Technology,44 suggesting that localized oHSV application 
induces activation of immune effectors both in the TME 
and systemically. This could provide an explanation for 
the induced antitumor memory detected in our rechal-
lenge experiment. tdLNs are key regulators in antitumor 
immune responses and analysis of specific memory T 
cell subpopulations within tdLNs by flow cytometry 
using markers such as CD44 and CD62L for effector 
and central memory, would provide further insight into 
treatment strategies and potential virus- induced thera-
peutic tumor vaccination effects. Tumor antigens drain 
primarily to tdLNs through transportation by CD103+ 
 on D
ecem













14 Crespo- Rodriguez E, et al. J Immunother Cancer 2020;8:e000698. doi:10.1136/jitc-2020-000698
Open access 
dendritic cells (DCs) which leads to priming of T cells, 
and these lymph nodes have been shown to control the 
magnitude of therapeutic efficacy to aPD-1 checkpoint 
therapy in mouse models.50 Overall, further analysis of 
the functional role of APC populations in tdLNs (and 
beyond in the spleen) would be worthwhile, in particular 
to inform the clinical uncertainty around whether treat-
ment of tdLNs, by surgery and/or radiotherapy, is likely to 
enhance or restrict priming of effective antitumor immu-
nity. Of note is our finding that, although the NanoString 
data did not suggest any major contribution of DCs to 
immune changes in the tumor, flow cytometry analysis of 
conventional DCs (CD45+/CD11c+/MHCII+) revealed 
low numbers that decreased in the tumors with treatment 
at 10 days, while significant upregulation was seen in 
tdLNs (data not shown). This illustrates how changes in 
numbers and activation status of various immune cells in 
both tumor and tdLNs are likely time- point- specific and 
might vary between models, as well as being influenced 
by levels of virus affecting the balance between priming 
of antiviral and antitumoral responses.
ConClusIons
Our data support the potential for successful immuno-
therapy in aggressive, BRAF- mutant thyroid cancer. BRAFi 
alone instigated limited changes only in the immune 
TME, but these were significantly boosted, and associated 
with effective therapy, on addition of immunostimula-
tory intratumoral oncolytic HSV injection. Gene expres-
sion analysis and flow cytometry profiling of tumors and 
draining lymph nodes confirmed activation of NK cell 
and T cell immunity by oHSV/BRAFi treatment, which 
was predominantly virus- driven, and directed successful 
incorporation of anti- CTLA-4 or anti- PD-1 into triple 
combination treatment regimens. Combining the cyto-
toxic and/or immunogenic effects of BRAFi and oHSV 
to generate a favorable immune response in the context 
of drug- mediated tumor cell kill, which can be further 
boosted by immune- checkpoint blockade, is worthy of 
further testing in the clinic.
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